Hepatic stellate cell apoptosis pathway proteins (HSC apoptosis pathway proteins)

Hepatic stellate cell (HSC) apoptosis pathway proteins comprise a complex network of molecules that regulate the programmed cell death of activated HSCs, which are the primary drivers of liver fibrosis (ResearchGate, 2006; NIH, 2024). In the healthy liver, HSCs remain in a quiescent state; however, chronic injury triggers their activation into myofibroblast-like cells that produce excessive extracellular matrix (ECM) (NIH, 2017). The resolution of fibrosis is fundamentally linked to the clearance of these activated cells, primarily through the induction of apoptosis (Frontiers, 2012). Key proteins involved in this process include members of the Bcl-2 family (such as Bcl-2, Bax, and Mcl-1), various caspases (Caspase-3, -8, -9), and death receptors like Fas and TRAIL receptors (NIH, 2008; NIH, 2009). Survival signaling pathways, including NF-kappaB, PI3K/Akt, and JAK/STAT, often counteract apoptosis in activated HSCs, contributing to the persistence of fibrosis (NIH, 2008; NIH, 2024). Therapeutic interventions targeting these proteins aim to shift the balance toward cell death, thereby promoting the regression of scar tissue (MDPI, 2021). Several pharmacological agents, including repurposed drugs like celecoxib and sulfasalazine, as well as experimental compounds like gliotoxin, have been shown to induce HSC apoptosis in preclinical models (ResearchGate, 2006; NIH, 2009). However, a major challenge in targeting these pathway proteins is achieving cell-type specificity to avoid damaging healthy hepatocytes or other non-target tissues (rug.nl, 2004). Successful modulation of this pathway represents a promising strategy for treating chronic liver diseases such as cirrhosis and non-alcoholic steatohepatitis (NASH) (NIH, 2024).

Other names

HSC apoptosis regulatorsLiver fibrosis resolution proteinsMyofibroblast apoptosis pathwayHSC apoptosis signaling pathway

Induction of apoptosis in activated hepatic stellate cells (HSCs) by modulating the expression of pro-apoptotic (e.g., Bax) and anti-apoptotic (e.g., Bcl-2, Mcl-1) proteins, activating the caspase cascade, or inhibiting survival signaling pathways such as NF-kappaB and PI3K/Akt (ResearchGate, 2006; NIH, 2008; NIH, 2009).